UPyTher is a preclinical stage drug-development company focused on developing cutting-edge medicines using its proprietary formulation technology. The company addresses diseases located in complex, hard-to-treat locations in the body with significant unmet medical needs.

For its initial focus, UPyTher is leveraging its unique formulations to create novel medicines specifically designed for the peritoneal cavity, targeting peritoneal cancers—currently deemed untreatable due to the lack of effective methods to deliver medicines to this area.

UPyTher’s portfolio features a new generation of drug products that are specifically optimized for local administration directly into the peritoneal cavity. This approach ensures local, prolonged, exposure to peritoneal tumors, significantly enhancing treatment efficacy. By maximizing the therapeutic impact at the tumor site while minimizing systemic exposure, UPyTher’s drug products have the potential to disrupt current treatment options for peritoneal cancer, offering improved outcomes with reduced toxicity for patients.

UPyTher’s lead product, based on a well-known compound, combines the commercial potential of a new drug with a cost-effective, low-risk development pathway. This product not only addresses a critical need in peritoneal oncology but also serves as a proof-of-concept for UPyTher’s proprietary platform formulation technology. By demonstrating the platform’s versatility and efficacy, the lead product paves the way for UPyTher’s ongoing pipeline programs with new mechanism therapeutics, including immunotherapies and targeted therapies, to unlock the peritoneal oncology market.

All of UPyTher’s products are supported by strong patent protection until 2043, with additional market exclusivity rights available upon regulatory approval from agencies like the EMA and FDA.

To date, the company has secured €3 million in equity and non-dilutive funding to demonstrate preclinical proof of concept and safety for its two lead products, targeting peritoneal cancers linked to colorectal and ovarian origins. UPyTher is now seeking to raise €8 million in a Series A round by Q3 2025 to establish clinical PoC for its lead product in 2027.